Pre-made Prezalumab benchmark antibody ( Whole mAb, anti-ICOSLG/B7RP1 therapeutic antibody, Anti-B7-H2/B7H2/B7h/CD275/GL50/ICOS-L/ICOSL/LICOS Antibody) for drug discovery and mechanism of action (MOA) research

Cat No.: GMP-Bios-ab-456

Pre-Made Prezalumab biosimilar, Whole mAb, Anti-ICOSLG/B7RP1 Antibody: Anti-B7-H2/B7H2/B7h/CD275/GL50/ICOS-L/ICOSL/LICOS therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Prezalumab is an IgG2 type monoclonal antibody designed to bind to ICOSL, inhibiting the interaction between ICOSL and ICOS and reducing the body's autoimmune response.

Order information


* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No. Package List Price(In USD) Discount off Discount Price
GMP-Bios-ab-456-1mg 1mg 3090 30% 2163

Size: 1mg | 10mg | 100mg



Description

Products Name (INN Index) Pre-Made Prezalumab biosimilar, Whole mAb, Anti-ICOSLG/B7RP1 Antibody: Anti-B7-H2/B7H2/B7h/CD275/GL50/ICOS-L/ICOSL/LICOS therapeutic antibody
INN Name Prezalumab
TargetB7RP1
FormatWhole mAb
DerivationHuman
Species ReactivityHuman
CH1 IsotypeIgG2
VD LCKappa
Highest_Clin_Trial (Jan '20)Phase-II
Est. StatusDiscontinued
100% SI Structure6x4t:BE:DF
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2015
Year Recommended2016
CompaniesAmgen;MedImmune
Conditions Approvedna
Conditions Activena
Conditions DiscontinuedCutaneous lupus erythematosus;Psoriasis;Sjogren's syndrome;Systemic lupus erythematosus
Development Techna